- Home
- INDP vs RDHL Comparison
INDP vs RDHL Comparison
Compare INDP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INDP | RDHL |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | INDP | RDHL |
|---|---|---|
| Price | $1.56 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.0K | ★ 95.6K |
| Earning Date | 03-12-2026 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $1.65 | $0.91 |
| 52 Week High | $47.60 | $6.26 |
Technical Indicators
Market Signals| Indicator | INDP | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 32.60 |
| Support Level | $2.60 | $1.26 |
| Resistance Level | $2.66 | $1.30 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 1.87 | 0.00 |
Price Performance
Historical ComparisonAbout INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.